ID: ALA5205480

Max Phase: Preclinical

Molecular Formula: C24H26ClN5O6

Molecular Weight: 515.95

Associated Items:

Representations

Canonical SMILES:  C=CC(=O)Nc1cc(Nc2ncc(Cl)c(O[C@@H]3CO[C@H]4[C@@H]3OC[C@H]4O)n2)ccc1N1C[C@@H]2C[C@H]1CO2

Standard InChI:  InChI=1S/C24H26ClN5O6/c1-2-20(32)28-16-5-12(3-4-17(16)30-8-14-6-13(30)9-33-14)27-24-26-7-15(25)23(29-24)36-19-11-35-21-18(31)10-34-22(19)21/h2-5,7,13-14,18-19,21-22,31H,1,6,8-11H2,(H,28,32)(H,26,27,29)/t13-,14-,18+,19+,21+,22+/m0/s1

Standard InChI Key:  MXJZKDHDEKITDX-WRRICFGBSA-N

Associated Targets(Human)

Tyrosine-protein kinase JAK1 8569 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Tyrosine-protein kinase JAK2 12915 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Tyrosine-protein kinase JAK3 8349 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Tyrosine-protein kinase TYK2 5029 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 515.95Molecular Weight (Monoisotopic): 515.1572AlogP: 1.88#Rotatable Bonds: 7
Polar Surface Area: 127.30Molecular Species: NEUTRALHBA: 10HBD: 3
#RO5 Violations: 1HBA (Lipinski): 11HBD (Lipinski): 3#RO5 Violations (Lipinski): 2
CX Acidic pKa: 13.21CX Basic pKa: 2.32CX LogP: 2.21CX LogD: 2.21
Aromatic Rings: 2Heavy Atoms: 36QED Weighted: 0.47Np Likeness Score: -0.27

References

1. Li S, Si H, Song X, Lei C, He X, Wang J, Liu Y, Zhou Y, Song JG, Peng L, Tang X, Chan S, Ren X, Tu Z, Li Z, Wang Z, Zhang Z, Ding K..  (2022)  Discovery of Hexahydrofuro[3,2-b]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant.,  65  (15.0): [PMID:35860875] [10.1021/acs.jmedchem.2c00922]

Source